PRCT Overview

PROCEPT BioRobotics Corporation is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). It designed Aquablation therapy to deliver outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH that is independent of prostate size and shape and delivers resection independent of surgeon experience. It manufactures the robotic systems, the single-use disposable handpiece, integrated scope and other accessories at its facility in San Jose, California. Each robotic system is shipped to its customers with a third-party manufactured ultrasound system and probe.

Wall Street analysts forecast PRCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRCT is51.75 USD with a low forecast of 38.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Procept Biorobotics Corp revenue for the last quarter amounts to 83.13M USD, increased 20.20

Procept Biorobotics Corp. EPS for the last quarter amounts to -0.56 USD, increased 24.44

Procept Biorobotics Corp (PRCT) has 888 emplpoyees as of June 20 2026.

Today PRCT has the market capitalization of 1.24B USD.